Caroline Ekblad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Caroline Ekblad has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anna Baierl
EnzyTag BV, Daelderweg 9, NL-6361 HK Nuth, The Netherlands
1 shared publication - Anna Orlova
Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden
1 shared publication - Anzhelika Vorobyeva
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
1 shared publication - Fredrik Y. Frejd
Department of Immunology, Genetics and Pathology, Uppsala University, 751 85 Uppsala, Sweden
1 shared publication - Leendert J. van Den Bos
EnzyTag BV, Daelderweg 9, NL-6361 HK Nuth, The Netherlands
1 shared publication - Olof Widmark
Affibody AB, 171 65 Solna, Sweden
1 shared publication
Latest Publications
- Open Access
- 19 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2519
Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis
Targeted molecular radiation therapy is a promising emerging treatment modality in oncology, and peptide synthesis may shorten the time to reach the clinical stage. In this study, we have explored Chemo-Enzymatic Peptide Synthesis, or CEPS, as a new means of producing a therapeutic HER2 targeted Affibody® molecule, comprising a C-terminal albumin binding domain (ABD) for half-life extension and a total length of 108 amino acids. In addition, a DOTA moiety could be incorporated at N-terminus directly during the synthesis step and subsequently utilized for site-specific radiolabeling with the therapeutic radionuclide 177Lu. Retained thermodynamic stability as well as retained binding to both HER2 and albumin was verified. Furthermore, HER2 binding specificity of the radiolabeled Affibody molecule was confirmed by an in vitro saturation assay showing a significantly higher cell-bound activity of SKOV-3 (high HER2 expression) compared with BxPC3 (low HER2 expression), both in the presence and absence of HSA. In vivo evaluation in mice bearing HER2 expressing xenografts also showed specific tumor targeting as well as extended time in circulation and reduced kidney uptake compared with a HER2 targeted Affibody molecule without the ABD moiety. To conclude, we have demonstrated that CEPS can be used for production of Affibody-fusion molecules with retained in vitro and in vivo functionality.
- 19 November 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (11) , 2519
Open AccessBiologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis
Targeted molecular radiation therapy is a promising emerging treatment modality in oncology, and peptide synthesis may shorten the time to reach the clinical stage. In this study, we have explored Chemo-Enzymatic Peptide Synthesis, or CEPS, as a new means of producing a therapeutic HER2 targeted Affibody® molecule, comprising a C-terminal albumin binding domain (ABD) for half-life extension and a total length of 108 amino acids. In addition, a DOTA moiety could be incorporated at N-terminus directly during the synthesis step and subsequently utilized for site-specific radiolabeling with the therapeutic radionuclide 177Lu. Retained thermodynamic stability as well as retained binding to both HER2 and albumin was verified. Furthermore, HER2 binding specificity of the radiolabeled Affibody molecule was confirmed by an in vitro saturation assay showing a significantly higher cell-bound activity of SKOV-3 (high HER2 expression) compared with BxPC3 (low HER2 expression), both in the presence and absence of HSA. In vivo evaluation in mice bearing HER2 expressing xenografts also showed specific tumor targeting as well as extended time in circulation and reduced kidney uptake compared with a HER2 targeted Affibody molecule without the ABD moiety. To conclude, we have demonstrated that CEPS can be used for production of Affibody-fusion molecules with retained in vitro and in vivo functionality.